Zhang Y, et al. - Via this systematic review and meta-analysis, researchers compared increased dose with stable dose of inhaled corticosteroids (ICS) among adults and children with asthma. They analyzed 8 trials including 3866 patients. The trials were identified from Medline, EMBASE, and Cochrane Central Register of Controlled Trials searched from inception to August 02, 2018. This study included randomized clinical trials that involved adults or children with asthma and compared increased doses vs stable doses of ICS for home management of asthma exacerbations. In order to attenuate the risk of needing a course of systemic corticosteroids in individuals with an asthma exacerbation, increasing ICS dose as part of a self-initiated action plan was supported by current evidence of moderate quality gained in this study. However, no evidence was found for influence on hospital admissions or unscheduled physician visits, and an increased risk of non-serious adverse events was reported in relation to an increased ICS dose.